Trial of Docetaxel Versus Vinorelbine as 1st Line Treatment in Elderly Patients With Non-Small-Cell Lung Cancer (NSCLC)

Sponsor
Hellenic Oncology Research Group
Study ID
NCT00441922
Phase
PHASE3
Status
Completed

Conditions

Eligibility Criteria

Sex
ALL
Age
65 Years - 80 Years
Healthy Volunteers
Not accepted

Interventions

  • Docetaxel — DRUG
    Docetaxel at the dose of 38 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles
  • Vinorelbine — DRUG
    Vinorelbine at the dose of 25 mg/m2 IV on days 1 and 8 every 3 weeks for 6 consecutive cycles

Study Details

This trial will compare the efficacy of docetaxel versus vinorelbine as first-line treatment in elderly patients with advanced NSCLC.

Key Dates

Start date
Jan 31, 2003
Status verified
Oct 2008
Primary completion
Jan 31, 2008
Completion
Jan 31, 2008

Study Design

Enrollment
166 participants (estimated)
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT

Arms

  • Experimental: 1
    D
  • Experimental: 2
    V

Primary Outcome Measure

Overall survival between the two treatment arms [ Time Frame: 1 year ]

Related Studies